| 1 |
Development of a CD33.targeted lead antibody for the treatment of AML based on a novel innovative antibody platform technology |
| Antibody |
Cancer |
CD33 |
Lead |
Centenaire Biosciences |
RS-2023-00283660 |
|
| 2 |
Development of lead immunotherapy agent for cancer using IL.36 receptor agonist antibody |
| Antibody |
Melanoma |
IL.36 |
Hit |
Daegu Gyeongbuk Institute of Science & Technology(DGIST) |
RS-2023-00283446 |
|
| 3 |
Novel bispecific antibodies development for Metastatic CastrationResistant Prostate Cancer |
| Antibody |
Cancer |
PSMA/CD137 |
Lead |
Ab Clon Inc. |
RS-2023-00283056 |
|
| 4 |
Preclinical Development of Anti.FGFR3 ADC for the Treatment of Bladder Cancer and Brain Tumor |
| Antibody |
Glioblastoma |
FGFR3 |
Preclinical |
Aimedbio |
RS-2023-00282706 |
|
| 5 |
Development of antibody against specific target expressed in the tumor microenvironment |
| Antibody |
Cancer |
HGF |
Lead |
Seoul National University |
RS-2023-00258823 |
|
| 6 |
Development of tumor ECM.modifying bispecific antibody for cancer immunotherapy |
| Antibody |
TNBC, NSCLC, PC |
DDR1, TGF.β |
Hit |
POSTECH |
RS-2023-00258678 |
|
| 7 |
Derivation of First-in-Class therapeutic antibody candidate for the treatment of claudin-3 overexpressing solid cancers |
| Antibody |
CLDN3hi solid cancer |
CLDN3 |
Candidate |
Abion, Inc. |
RS-2023-00218182 |
|
| 8 |
Generation of the lead antibody targeting APP, a novel immuno-oncology target |
| Antibody |
Solid cancer |
APP |
Lead |
Genome & Company |
RS-2023-00217717 |
|
| 9 |
Candidate development of anti-TCTP neutralizing candidate (BIO101) for the treatment of solid tumors |
| Antibody |
Solid Cancer |
TCTP |
Candidate |
Boostimmune, Inc. |
RS-2023-00217478 |
|
| 10 |
Development of a Novel Immunotherapeutics with Tumor-associated Macrophage(TAM) Suppression Mechanism |
| Antibody |
NSCLC |
CHI3L1 |
Lead |
Senelix |
RS-2022-00166446 |
|
| 11 |
Development of a new therapeutic agent for bone metastasis cancer through the development of anti-****** humanized antibody |
| Antibody |
Solid Tumor |
CXCL16 |
Hit |
Cellus |
RS-2022-00166371 |
|
| 12 |
IND approval and securing IMP batch for GENA-104A16, an immune checkpoint inhibitor targeting CNTN4 |
| Antibody |
Solid Tumor |
CNTN4 |
Preclinical |
Genome&Company |
RS-2022-00166157 |
|
| 13 |
Development of hit/lead antibody neutralizing TMPRSS4, a novel therapeutic target for the treatment of non-small cell lung cancer |
| Antibody |
NSCLC |
TMPRSS4 |
Hit |
Korea Research Institute of Bioscience and Biotech |
RS-2022-00166100 |
|
| 14 |
Development for immunotherapeutics targeting tumor-associated macrophages |
| Antibody |
Solid Tumor |
TREM2 |
Lead |
AimedBio Inc |
RS-2022-00166068 |
|
| 15 |
Development of a non-clinical candidate for colorectal cancer treatment RACE-111 (EGFRX4-1BB) bispecific antibody |
| Antibody |
Colorectal cancer |
EGFR, 4-1BB |
Candidate |
CTCELLS |
RS-2022-00166009 |
|
| 16 |
Development of immuno-cancer antibodies that improves single and/or combination anti-cancer efficacy by improving immune suppressive tumor microenvironments |
| Antibody |
Solid Tumor |
B7-H3/TGF-β |
Candidate |
Theranotics |
HN22C0442 |
|
| 17 |
Development of a first-in-class immunotherapy for treatment of non-small cell lung cancer with PD-L1 negative/low |
| Antibody |
Lung Cancer |
IGSF1 |
Preclinical |
Wellmarkerbio |
HN22C0157 |
|
| 18 |
Development of cancer cachexia treatment using anti-GFRAL antibody |
| Antibody |
Cancer Cachexia |
GFRAL |
Candidate |
TroyY |
HN22C0147 |
|
| 19 |
Development of complement C4d X CD3 BiTE |
| Antibody |
Cancer |
C4d, CD3 |
Hit |
Seoul National University |
HN22C0061 |
|
| 20 |
Candidate development of PD-L1xIL-2v immuno-oncology (MB201) applying a novel bispecific antibody platform technology |
| Antibody |
Solid Tumor |
PD-L1, IL-2 |
Candidate |
MustBio Inc |
HN22C0050 |
|
| 21 |
Nonclinical study of the immuno-oncological therapeutic antibody against novel immune checkpoint CD300c |
| Antibody |
Lung cancer, Colorectal, Breast cancer |
CD300c |
Preclinical |
CentricsBio Inc. |
HN21C1400 |
|
| 22 |
Completion of YBL-006 phase I trial;
a novel immune checkpoint inhibitor |
| Antibody |
Squamous cell carcinoma, Renal cell carcinoma |
PD-1 |
Phase 1 |
Y-Biologics |
HN21C1391 |
|
| 23 |
Preclinical study of IOH-001, a Bispecific Antibody immunotherapy targeting PD-L1 and CD47 |
| Antibody |
TNBC |
PD-L1, CD47 |
Preclinical |
ImmuneOncia |
HN21C1388 |
|
| 24 |
Development of humanized antibody for lung cancer treatment targeting DDOST protein |
| Antibody |
Lung cancer |
DDOST |
Lead |
Hanyang University |
HN21C1351 |
|
| 25 |
Development of anti-HLA-G/CD3 T-cell engaging bispecific antibody for the treatment of CRC patients |
| Antibody |
Colorectal cancer |
HLA-G, CD3 |
Candidate |
Y-Biologics |
HN21C1337 |
|
| 26 |
Identification of leading substances for the treatment of esophageal cancer and breast cancer based on PTK7-neutralizing humanized antibodies |
| Antibody |
Esophageal squamous cell carcinoma, TNBC, PTK7 expression cancer |
PTK7 |
Lead |
Yonsei University |
HN21C1214 |
|
| 27 |
Phase 1 clinical development of anti-cancer bispecific antibody ABL501 targeting LAG-3 and PD-L1 |
| Antibody |
NSCLC, Lung cancer, Colorectal cancer, Gastric cancer, Triple-Negative Breast Cancer, Ovarian cancer |
PD-L1, LAG-3 |
Phase 1 |
ABL Bio |
HN21C0979 |
|
| 28 |
Development of anti-VISTA antibody PMC-309 for the treatment of NSCLC |
| Antibody |
NSCLC |
VISTA |
Preclinical |
PharmAbcine Inc. |
HN21C0774 |
|
| 29 |
ABL103, A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivo antitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment |
| Antibody |
Solid Tumor |
B7-H4, 4-1BB |
Preclinical |
ABLBio |
HN21C0614 |
|
| 30 |
Next-generation anti-TIGIT antibody (7043H1E) with enhanced Fc function |
| Antibody |
Solid Tumor |
TIGIT |
Candidate |
HanAll BioPharma |
HN21C0596 |
|
| 31 |
Phase 1 clinical trial of CKD-702, bispecific antibody, in NSCLC |
| Antibody |
NSCLC |
c-MET, EGFR |
Phase 1 |
Chong Kun Dang pharmaceutical Corp. |
HN21C0551 |
|
| 32 |
A study on development of lead antibodies targeting an immune checkpoint inhibitor refractory factor for metastatic melanoma |
| Antibody |
Metastatic malignant melanoma |
Oncokine-2 |
Hit |
Korea university |
HN21C0486 |
|
| 33 |
Development of antibody-based therapeutics neutralizing a novel target for the treatment of metastatic colorectal cancer |
| Antibody |
Metastatic colorectal cancer |
CCSP-2 |
Hit |
ASAN Medical Center |
HN21C0207 |
|
| 34 |
Development of hit and lead asymmetric anti-CD20xCD55 bispecific antibodies containing Fc variants with maximized serum half-lives and effector functions for cancer therapy |
| Antibody |
Non-Hodgkin lymphoma, CLL |
CD20, CD55 |
Hit |
Korea University |
HN21C0103 |
|
| 35 |
Development of lead antibodies targeting an immune- checkpoint inhibitor refractory factor for metastatic non-small cell lung carcinoma |
| Antibody |
Lung cancer |
NSN-001 |
Lead |
NEX-I, Inc |
HN21C1323 |
|
| 36 |
Lead selection of PD-L1xCD3 targeted immuno-oncology (MB101) applying a novel bispecific antibody platform technology |
| Antibody |
Solid Tumor |
PD-L1, CD3 |
Lead |
MustBio Inc |
HN21C0985 |
|
| 37 |
Development of anti-PD-L1 x anti-SIRPα bispecific antibody that systemically activates both innate and adaptive anti-tumor immune system |
| Antibody |
Solid Tumor |
PD-L1, SIRPα |
Hit |
PharmAbcine Inc. |
HN21C0973 |
|
